Xeris Biopharma Holdings Forecast, price target & analysts
Xeris Biopharma Holdings Target price 2026 - Analyst rating & recommendation
Xeris Biopharma Holdings Classifications & Recommendation:
Xeris Biopharma Holdings Price Target
| Target Price | $10.20 |
| Price | $7.35 |
| Potential |
38.78%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Xeris Biopharma Holdings 2027 .
The average Xeris Biopharma Holdings target price is $10.20.
This is
38.78%
register free of charge
$18.90
157.14%
register free of charge
$8.08
9.93%
register free of charge
|
|
| A rating was issued by 12 analysts: 10 Analysts recommend Xeris Biopharma Holdings to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Xeris Biopharma Holdings stock has an average upside potential 2027 of
38.78%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 203.07 | 293.17 |
| 23.89% | 44.37% | |
| EBITDA Margin | -11.23% | 18.41% |
| 44.52% | 263.97% | |
| Net Margin | -27.01% | -2.50% |
| 28.90% | 90.74% |
8 Analysts have issued a sales forecast Xeris Biopharma Holdings 2025 . The average Xeris Biopharma Holdings sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Xeris Biopharma Holdings EBITDA forecast 2025. The average Xeris Biopharma Holdings EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Xeris Biopharma Holdings Analysts have issued a net profit forecast 2025. The average Xeris Biopharma Holdings net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.37 | -0.04 |
| 17.78% | 89.19% | |
| P/E | negative | |
| EV/Sales | 4.60 |
9 Analysts have issued a Xeris Biopharma Holdings forecast for earnings per share. The average Xeris Biopharma Holdings EPS is
This results in the following potential growth metrics and future valuations:
Xeris Biopharma Holdings...
Current Xeris Biopharma Holdings Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Dec 09 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | Oct 29 2025 |
| Oppenheimer |
Locked
➜
Locked
|
Locked | May 09 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Dec 09 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Oct 29 2025 |
|
Locked
Oppenheimer:
Locked
➜
Locked
|
May 09 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Nov 11 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
